Treatment of patients with advanced soft tissue sarcoma: Disappointment or challenge?

Current Opinion in Oncology

Volumn 19, Issue 4, 2007, Pages 336-340

  Kasper, Bernd ^a   Gil, Thierry ^b   Awada, Ahmad ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b JULES BORDET INSTITUTE   (Belgium)

Author keywords

Molecular targeted therapies; New treatment strategies; Soft tissue sarcoma

Indexed keywords

AE 941; AP 23573; BEVACIZUMAB; BIRICODAR; BROSTALLICIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 MONOCLONAL ANTIBODY; DOXORUBICIN; EVEROLIMUS; FLAVOPIRIDOL; GEFITINIB; IFOSFAMIDE; IMATINIB; IMMUNOMODULATING AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MONOCLONAL ANTIBODY; OBLIMERSEN; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PROTEIN BCL 2; SEMAXANIB; SORAFENIB; STA 4783; TEMSIROLIMUS; TRABECTEDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT;

ANTISENSE THERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG INDUCED DISEASE; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LEIOMYOSARCOMA; LIPOSARCOMA; LOW DRUG DOSE; MELANOMA; MOLECULAR BIOLOGY; MONOTHERAPY; MOUTH PAIN; MULTIPLE CYCLE TREATMENT; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RASH; REVIEW; SOFT TISSUE SARCOMA;

ANTIBIOTICS, ANTINEOPLASTIC; HUMANS; PROGNOSIS; RECEPTORS, GROWTH FACTOR; SARCOMA; SIROLIMUS;

EID: 34250020728     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32812143ef     Document Type: Review

References (32)

1. Fahn W, Issels RD. Emerging treatments for soft tissue sarcoma of adults. Expert Opin Emerg Drugs 2004; 9:313-343.
2. Yi-Shin Kuo D, Timmins P, Blank SV, et al. Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol Oncol 2006; 100:160-165.
3. Tsai YC, Wu CT, Hong RL. Response of refractory osteosarcoma to thalidomide and celecoxib. Lancet Oncol 2005; 6:997-999.
4. D'Adamo DR, Anderson SE, Albritton K, et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft tissue sarcomas. J Clin Oncol 2005; 23:7135-7142.
5. Kuenen BC, Tabernero J, Baselga J, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003; 9:1648-1655.
6. Heymach JV, Desai J, Manola J, et al. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcoma. Clin Cancer Res 2004; 10:5732-5740.
7. Suttle AB, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumours [abstract]. Proc Am Soc Clin Oncol 2004; 23:208.
8. Balasubramanian L, Evens AM. Targeting angiogenesis for the treatment of sarcoma. Curr Opin Oncol 2006; 18:354-359. This excellent review discusses the role of angiogenesis in soft tissue sarcomas; the use of antiangiogeneic drugs and treatment strategies in sarcomas are presented.
9. Kapadia D, Fong L. CTLA-4 blockade: autoimmunity as treatment. J Clin Oncol 2005; 23:8926-8928.
10. Espenscheid J, Lamont J, Longmate J, et al. CTLA-4 blockade enhances the therapeutic effect of an attenuated poxvirus vaccine targeting p53 in an established murine tumor model. J Immunol 2003; 170:3401-3407.
11. Ayyoub M, Taub RN, Keohan ML, et al. The frequent expression of cancer/testis antigens provides opportunities for immunotherapeutic targeting of sarcoma. Cancer Immun 2004; 4:7.
12. Knight LA, Di Nicolantonio F, Whitehouse P, et al. The in vitro effect of gefitinib (Iressa) alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC Cancer 2004; 23:83.
13. Blay J, Le Cesne A, Whelan J, et al. Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: A phase II trial of EORTC Soft Tissue and Bone Sarcoma Group [abstract 9517]. Proc Am Soc Clin Oncol 2006; 24:18S.
14. Bode B, Frigerio S, Behnke S, et al. Mutations in the tyrosine kinase domain of the EGFR gene are rare in synovial sarcoma. Mod Pathol 2006; 19:541-547.
15. Thallinger C, Wolschek MF, Maierhofer H, et al. Mcl-1 is a novel therapeutic target for human sarcoma: synergistic inhibition of human sarcoma xenotransplants by a combination of mcl-1 antisense oligonucleotides with low-dose cyclophosphamide. Clin Cancer Res 2004; 10:4185-4191.
16. Joyner DE, Albritton KH, Bastar JD, Randall RL. G3139 antisense oligonucleotide directed against antiapoptotic Bcl-2 enhances doxorubicin cytotoxicity in the FU-SY-1 synovial sarcoma cell line. J Orthop Res 2006; 24:474-480. This is a fascinating report on the emerging use of Bcl-2 antisense treatment strategies in a preclinical model for synovial sarcoma.
17. Strumberg D. Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today 2005; 41:773-784.
18. D'Adamo DR, Keohan ML, Schwartz GK, et al. A phase II study of sorafenib in metastatic/recurrent sarcomas. Partial results of CTEP study 7060, emphasizing leiomyosarcomas [abstract 732]. In Proceedings of the 12th Annual Meeting of the Connective Tissue Oncology Society Meeting; 2-4 November 2006; Venice, Italy. Alexandria, VA: CTOS; 2006.
19. Okuno S. Mammalian target of rapamycin inhibitors in sarcomas. Curr Opin Oncol 2006; 18:360-362. An up-to-date review on use of mTOR inhibitors in the treatment of bone and soft tissue sarcomas is presented.
20. Chawla S, Tolcher A, Sankhala KK, et al. Updated results of a phase 2 trial of the novel mTOR inhibitor AP23573 in patients with advanced soft-tissue or bone sarcoma [abstract 665]. In Proceedings of the 12th Annual Meeting of the Connective Tissue Oncology Society Meeting; 2-4 November 2006; Venice, Italy. Alexandria, VA: CTOS; 2006.
21. Rossi F, Ehlers I, Agosti V, et al. Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor. Proc Natl Acad Sci USA 2006; 103:12843-12848.
22. Terry J, Lubieniecka JM, Kwan W, et al. Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin Cancer Res 2005; 11:5631-5638.
23. Sherman ML, Ryan C, Blackstein M, et al. Phase I/II study of STA-4783, a novel heat shock protein 70 (Hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcoma (STS) [abstract 9096]. Proc Am Soc Clin Oncol 2005; 24:9096.
24. Verweij J. Ecteinascidin-743 (ET-743): Early test or effective treatment in soft tissue sarcomas? J Clin Oncol 2005; 24:5420-5423.
25. Grosso F, Demetri GD, Blay JY, et al. Patterns of tumor response to trabectedin (ET743) in myxoid liposarcomas [abstract 9511]. Proc Am Soc Clin Oncol 2006; 24:18S. (abstract 9511).
26. Blay JY, vom Mehren M, Samuels BL, et al. Phase I study of trabectedin (T) in combination with doxorubicin (D) in patients with soft tissue sarcoma (STS) [abstract 612]. In Proceedings of the 12th Annual Meeting of the Connective Tissue Oncology Society Meeting; 2-4 November 2006; Venice, Italy. Alexandria, VA: CTOS; 2006.
27. Fayette J, Coquard IR, Alberti L, et al. ET-743: a novel agent with activity in soft-tissue sarcomas. Curr Opin Oncol 2006; 18:347-353. An excellent review of the antitumor activity of ET-743 in the treatment of soft tissue sarcomas is presented.
28. Leahy MG, Ray-Coquard I, Verweij J, et al. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2006; 43:308-315. This is the only report to provide detailed information on the clinical safety and efficacy of brostallicin in metastatic soft tissue sarcoma patients.
29. Misset JL, Gamelin E, Campone M, et al. Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors. Ann Oncol 2004; 15:1123-1129.
30. Bramwell VH, Morris D, Ernst DS, et al. Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracyclin-resistant advanced soft tissue sarcoma. Clin Cancer Res 2002; 8:383-393.
31. D'Adamo DR, Scheu K, Singer S, et al. A phase I trial of doxorubicin and flavopiridol in soft tissue sarcoma [abstract 9523]. Proc Am Soc Clin Oncol 2006; 24:18S.
32. Kelly WK, O'Connor OA, Krug LM, et al. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J Clin Oncol 2005; 23:3923-3931.